Dive Brief:

Merck KGaA, like other contract manufacturers such as Lonza, is betting the next big wave of demand will be for complex production of gene therapies and other products such as viral vaccines and immunotherapies. The gene therapy market will grow to about $10 billion by 2026 from $1 billion in 2018, the company said, citing estimates from Biotech Forecasts.

"Viral vector manufacturing has transitioned from a niche industry to the cornerstone of the future of biopharmaceuticals," said Udit Batra, head of Merck KGaA'slife science business, in a statement.

The German company has been on a spending spree in recent years, announcing plans to invest 1 billion euros in its global headquarters in Darmstadt, more than $400 million in two sites in Switzerland,and $70 million in a research and development hub expansion in Billerica, Massachusetts.

Carlsbad is already home to a Merck KGaA facility that has been involved in gene therapy since 1997, about the time that researchers beginning studying the potential for such treatments in people. At present, the site has 16 modular viral bulk manufacturing clean room suites and two fill/finish suites, Merck KGaA said.

With the new facility, the Carlsbad location will have 27 suites used in different parts of the manufacturing process and will support production at the 1000-liter scale using single-use equipment, Merck KGaA said.

The company also has a manufacturing facility in Glasgow that produces intermediates and final products for gene therapy and viral vaccines.

Merck KGaA, established in 1688, is majority owned by descendants of the original founder and had sales of 16.2 billion euros last year. The U.S. pharmaceutical giant Merck was once a subsidiary but is no longer associated with its German namesake.

View post:
Merck KGaA to spend $110M on new gene therapy facility in California - BioPharma Dive

Comments are closed.